{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"IMMUNO-BIL","nct_id":"NCT03704480","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immuno-bil-nct03704480. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMMUNO-BIL","arms":[{"description":"One cycle equals 4 weeks (D1=D28);\n\nDurvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.\n\nTremelimumab: 300 mg by IV infusion on D1 at cycle 1 only.","label":"Amended ARM A","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"conditions":["Advanced Biliary Tract Carcinoma"],"enrollment":{"count":106,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Tremelimumab","otherNames":["CP-675"],"type":"DRUG"}],"last_update":"2025-07-23","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","official_title":"Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-07-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in amended Arm A","timeFrame":"At 6 months"}],"references":[{"citation":"Boileve A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanie H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. Eur J Cancer. 2021 Jan;143:55-63. doi: 10.1016/j.ejca.2020.10.027. Epub 2020 Dec 3.","pmid":"33279854","type":"DERIVED"}],"start_date":{"date":"2018-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.","url":"https://clinicaltrials.gov/study/NCT03704480"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immuno-bil-nct03704480"}